-
Track & Monitor
Venture Capital Investment Trends in Pharma - Q2 2026
This report analyzes the venture capital (VC) investment activity in Q2 2026 in the Pharma sector.
-
Track & Monitor
Merger and Acquisition Trends in Pharma - Q2 2026
This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
-
Sector Analysis
Emerging Market Outsourcing Report, Q2 2026
This expert outsourcing report is a comprehensive look at the pharmaceutical manufacturing landscape for emerging markets in Q2 2026, including analysis of news and trends affecting contract manufacturing organizations (CMOs) and the identification of recent contract service agreements, mergers, acquisitions, and financing among CMOs. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the pharmaceutical value chain that will provide insights into API (biologics and chemical) as well as dose manufacturing and...
-
Sector Analysis
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis (FSGS) Therapeutics. In 2025, there were 37,049 incident cases of FSGS in the 16 countries covered in GlobalData’s epidemiology forecast. In 2021, the most recent guideline for physicians for diagnosis and treatment of FSGS was established across seven major markets (US, France, Germany, Italy, Spain, the UK, and Japan) by the Kidney Disease Improving Global Outcomes (KDIGO). Over roughly the past three years,...
-
Sector Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics. In 2025, there were 308.98 million 12- month total diagnosed prevalent cases of GERD in the 16 countries covered in GlobalData’s epidemiology forecast. The management of GERD typically includes a mix of lifestyle adjustments, medication-based treatments, and, in certain cases, surgical or procedural options. Key therapy classes showing this effect include PPIs, histamine H2 receptor (HRH2) antagonists, and dopamine receptor...
-
Sector Analysis
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in IgA Nephropathy (Berger’s Disease) Therapeutics. • In 2025, there were 102,155 incident cases of Berger's disease in the 16 countries covered in GlobalData’s epidemiology forecast. • Berger's disease is primarily managed with blood pressure medication like ACE inhibitors or ARBs to protect the kidneys. For high-risk patients, corticosteroids and newer targeted therapies are also available to slow the disease's progression. • The Berger's disease pipeline holds...
-
Sector Analysis
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
Hepatocellular carcinoma (HCC) arises from the hepatocyte cells in the liver and is the most common primary liver cancer, accounting for approximately 90% of all primary cancers of the liver (Asafo-Agyei and Samant, 2023). HCC has a high mortality rate and is the third leading cause of cancer deaths annually worldwide (Singal, Kanwal and Llovet, 2023). Major risk factors for HCC include infection with the hepatitis B virus (HBV), infection with the hepatitis C virus (HCV), and high alcohol consumption...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Obesity is a chronic disease characterized by the accumulation of excess body fat. Individuals living with obesity may undergo metabolic dysfunction on account of excess adipose tissue. The diagnostic criteria for obesity are met by a body mass index (BMI) of 30kg/m2 or more (NIH, 2022a). This can lead to a state of chronic systemic inflammation, as well as a predisposition to comorbidities such as diabetes and cardiovascular disease. Clinical interventions aim to manage obesity by encouraging patient behavioral change,...
-
Sector Analysis
Hepatitis C Virus: Epidemiology Report and Forecast to 2035
Hepatitis C is an inflammatory liver disease caused by the hepatitis C virus (HCV). HCV primarily spreads through direct blood contact, which can happen via needle/syringe sharing in people who inject drugs, unscreened blood transfusions and unsterilized medical equipment, and sexual contact involving blood. Additionally, vertical transmission of HCV can occur (Public Health England, 2018). Many people with hepatitis C are asymptomatic and unaware that they have the infection, with only approximately a quarter of patients exhibiting symptoms, including fatigue,...
-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Epilepsy is a neurological condition defined by repeated, unpredictable seizures resulting from abrupt, chaotic, and intense electrical activity among brain cells (World Health Organization, 2024a). Globally, it ranks as one of the most widespread neurological disorders (World Health Organization, 2024a). This chronic condition can develop at any point in a person's life. A diagnosis typically occurs after an individual experiences at least one seizure and sees a specialist, who evaluates detailed accounts of both the pre-seizure warning signs and the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.